NASDAQ: LPTXLeap Therapeutics Inc Stock Ownership - Who owns Leap Therapeutics?
Insider buying vs selling
Have Leap Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jason Baum | Chief Scientific Officer | 2025-03-28 | 6,604 | $0.32 | $2.09kSell |
| Christine Granfield | VP Head of Reg AffairsQual | 2025-03-28 | 6,604 | $0.32 | $2.09kSell |
| Augustine Lawlor | Chief Operating Officer | 2025-03-28 | 7,797 | $0.32 | $2.47kSell |
| Christopher Mirabelli | Chairman of the Board | 2025-03-28 | 6,672 | $0.32 | $2.12kSell |
| Douglas E. Onsi | CEOCFOPres.GCTreas.Sec. | 2024-11-13 | 2,136 | $2.82 | $6.02kBuy |
| James H. Cavanaugh | Director | 2024-11-13 | 213 | $2.82 | $600.66Buy |
| Christopher Mirabelli | Chairman of the Board | 2024-11-13 | 2,136 | $2.82 | $6.02kBuy |
| Augustine Lawlor | Chief Operating Officer | 2024-11-13 | 2,136 | $2.82 | $6.02kBuy |
LPTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when LPTX insiders and whales buy or sell their stock.
LPTX Shareholders
What type of owners hold Leap Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Perceptive Advisors LLC | 20.46% | 8,476,496 | $2.80M | Insider |
| Beigene Ltd | 17.73% | 7,348,437 | $2.42M | Insider |
| Gilead Sciences Inc | 12.84% | 5,319,148 | $1.76M | Insider |
| Gilead Sciences Inc | 12.84% | 5,319,148 | $1.76M | Institution |
| Healthcare Ventures IX LP | 10.00% | 4,144,804 | $1.37M | Insider |
| John W. Littlechild | 6.32% | 2,618,406 | $864.07k | Insider |
| Samsara Biocapital LLC | 5.89% | 2,442,352 | $805.98k | Institution |
| Augustine Lawlor | 4.15% | 1,718,454 | $567.09k | Insider |
| Douglas E. Onsi | 3.72% | 1,542,971 | $509.18k | Insider |
| Lilly Co Eli | 3.57% | 1,479,307 | $488.17k | Insider |
LPTX vs Biotech Stocks
Leap Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.